Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Natural Growth, Advanced Techniques, Real Results.
Free Download: Stem Cell Therapy for Hair Regeneration
Disclaimer:
The information provided by R3 Stem Cell is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. The FDA considers stem cell therapy experimental at this point.
Any claims made on this website refer to procedures performed OUTSIDE of the USA. R3 Stem Cell has clinics in Mexico, Philippines, South Africa, Turkey, India, Pakistan.
Every day, R3 Stem Cell receives inquiries worldwide from individuals asking if stem cell therapy can help with hair loss. Spoiler alert: It can help a lot! In this guide, we’ll go through the basics of how stem cells work for regenerating hair, the latest research, and what to expect with a regenerative procedure.
The science of hair loss has been investigated for decades. It is understood that losing up to 100 hairs per day is perfectly normal. Any loss above this number with no replenishment however leads to eventual thinning of the hair. Male and female hair loss has multiple causes.
The hair follicle (HF) grows following a cycle of dynamic and complex processes, which mainly alternate in three phases: rapid growth (anagen), regression (catagen), and quiescence (telogen).
Although hair follicles are protected and maintained through their association with immune responses against pathogens and different tissue regeneration and healing processes, hair abnormalities or loss (alopecia) commonly occurs in both males and females of all ages, affecting quality of life, attractiveness, and self-esteem. Reportedly, alopecia can lead to psychiatric disorders and increased risks of diseases, such as myocardial infarction and metabolic syndrome.
Alopecia is broadly categorized into two subtypes: scarring or non-scarring. The scarring type comprises approximately 5% of all cases of alopecia and describes multiple subtypes of hair loss caused by unknown inflammatory mechanisms.
Androgenic Alopecia (AGA) is the most common cause of non-scarring hair loss, affecting 30-50% of men (male-pattern hair loss [MPHL]) and approximately 30% of middle-aged women (female-pattern hair loss [FPHL]). The disease manifests by progressive hair loss, usually in a pattern distribution. It can begin at any age after puberty, but the incidence increases with age.
The mechanisms of AGA are multiple, interlinked, and common to both MPHL and FPHL.
Among them is the hypothesis of oxidative stress (OS) and it has been demonstrated that AA is associated with systemic autoimmune activation in isolation as an acquired autoimmune disorder (AD) or as a comorbidity with diseases such as systemic lupus erythematosus (SLE). The miniaturization of hair follicles and decreased hair density occur in the affected scalp area of patients with AGA.
Terminal hair growth length is gradually reduced in this disease entity. Although the causes of miniaturization are unknown, genetic tendencies and androgen effects are thought to be associated with other factors that have not yet been clarified.
Alopecia areata (AA) is a common autoimmune disease characterized by hair loss. It affects more than 6.5 million people in the United States, has a worldwide prevalence of 0.1%-0.2%, and a lifetime risk of 2% in the general population. AA appears in extensive forms, such as progressive and diffusing hair loss (diffuse AA), a total loss of scalp hair (alopecia totalis), and complete loss of hair over the entire body (alopecia universalis). Patients with AA suffer from extensive hair loss that can have a devastating impact on their quality of life.
Hair follicles contain a variety of cell resources, such as melanocytic cells, epithelial cells, and stem cells from different developmental origins, which are capable of constantly renewing and regulating hair growth. The subjects of the greatest interest are the stem cells in the hair follicle. They can be stimulated to promote hair growth!
Restore your hair naturally—call us at (844) GET-STEM.
Only a few pharmacological treatment options have been approved for clinical use by regulatory bodies, such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Moreover, these conventional therapies which mainly include corticosteroids, minoxidil, and 5a-reductase inhibitors such as finasteride and dutasteride, face significant challenges.
Nonetheless, the treatment options for androgenic alopecia are limited, with a poor prognosis. Therapy for hair loss includes the use of glucocorticoids, minoxidil-based drugs, or hair transplantation, all of which present varying side effects. Therefore, these options are not usually recommended for patients with diffuse AA, AT, or AU.
Low level laser light therapy (LLLLT) is the only approved device by the FDA to treat androgenetic alopecia. Gupta et al, in a systematic review with meta-analysis from 2022, came to the conclusion that the only treatment option with strong evidence, for both males and females with androgenic alopecia is 5% minoxidil.
Get expert guidance on stem cell treatment for stroke. Call (844) GET-STEM.
If a new technology such as mesenchymal stem cell and exosome therapy could provide a long term solution for hair fall, it would and should become first line therapy. A regenerative therapy that can initiate spontaneous hair growth, negate the need for medications or injections and is a safe option should receive consideration.
Stem cell-based therapies have recently gained considerable attention as potential novel treatments, focusing on the reactivation of hair follicle stem cells and thus improving the growth, regeneration, and development of hair follicles.
A recent report indicated that mesenchymal stem cells were safe and effective for treating AA. In the report, 19 of 20 patients exhibited an increased hair diameter and significantly increased hair density within 3 to 6 months of treatment.
In 2018, Elmaadawi et al. reported findings from a study on the safety and efficacy of mesenchymal stem cells in 20 patients with AA and 20 patients with AGA. In this study, each patient received one intradermal dose of stem cells, and the impact was evaluated via immunostaining and digital dermoscopy after 6 months. No study patients experienced any side effects, and all subjects displayed significantly improved hair growth with no significant difference between the groups.
Human umbilical cord mesenchymal stem cells (MSCs) have proven useful in tissue repair and regeneration. Moreover, a study that utilized allogenic, minimally manipulated umbilical cord MSCs reported for the first time the successful treatment of AA and alopecia universalis.
Umbilical Cord-MSCs were isolated from the umbilical cord, immediately frozen, and stored at -197 C without any other manipulations including cell culture. Minimal manipulation of SCs reportedly results in safer and better proliferation and differentiation capacities than long-term cultured MSCs.
New treatment strategies for AA and related diseases are needed. Various studies have been attempted for the treatment of AA. Among them is the use of mesenchymal stem cells (MSCs), which has had remarkable success. MSCs are efficacious in the treatment of autoimmune diseases because they have anti-inflammatory and immunomodulatory properties.
In addition, MSC treatment is suitable as a new alternative treatment method for AA because MSCs promote hair growth and strengthen the hair. Based on these results, Ahn et al. transplanted umbilical cord mesenchymal stem cells to treat androgenic alopecia in 2 patients and alopecia universalis (AU) in 1 patient.
The therapeutic effect of MSCs on AA and related diseases is very high as shown in the patients presented here. Recurrence of AA and AU and side effects did not occur during the treatment and follow-up duration of at least 1 year. Based on these results, we expect that umbilical cord mesenchymal transplantation will be a safe and efficient alternative for the treatment of AA, AT, and AU.
Gentile et al. used mesenchymal stem cells in 11 patients (38 to 61 years old) affected by AGA in stages 3–5, as determined by the Norwood-Hamilton classification scale. In patients with hair loss in the frontal and parietal areas, the stem cell injections were administered exclusively to the front scalp, and placebo injections (i.e., normal saline) were administered to the parietal areas.
Similarly, in patients with hair loss limited to the parietal and vertex regions, stem cells were injected into the parietal region and placebos were injected into the scalp vertex. The hair density after 23 weeks increased by 29% for a treated area and by less than 1% for the placebo area. They hypothesized that stem cells can improve the formation of new follicles. No major side effects were reported.
Another study conducted by Gentile et al. in 2019 with 21 participants demonstrated that the average hair density among patients from the treatment group with mesenchymal stem cells increased by more than 30%, and from the placebo group it increased by less than 1% at 12 weeks after the treatment. There was no mention of the occurrence of any side effects. The study carried out by Zari et al. in a group of 140 consecutive adults with confirmed AGA sought to examine the efficacy of autologous cellular micrografts which contain mesenchymal stem cells. Efficacy was evaluated 1–6 months after treatment by analyzing the change of trichometry parameters, which showed that depending on the scalp region there was an increase in the mean hair density by 4.5–7.12 hair/cm2. No side effects were reported.
Kim et al. reported nine patients who were suffering from AGA with a single transplantation of autologous SVF in the upper scalp. Hair density of the ADSCs-treated side was significantly increased after 3 and 6 months of transplantation compared to the nontreated side (p = 0.01 and p = 0.009 per each). There was no mention of the occurrence of any side effects.
El-Khwalawany et al. analyzed the efficacy of the mesenchymal stem cells in 30 patients with AGA. Patients received one stem cell injection and a single 6-month follow-up session. The number of hairs increased from 130.87/cm2 to 151.93/cm2. Patients were asked about experienced pain during and after the procedure and 21 reported mild pain and 9 reported moderate pain. Other than that, no other side effects were reported.
According to the results of this review, the use of stem cell injections in female and male AGA appears to be a promising treatment option. In R3’s experience, 90% of patients with hair loss achieve success with stem cell and exosome therapy. It’s an exciting option for patients!
Learn how stem cells can help your hair—call (844) GET-STEM now.
How is the Stem Cell and Exosome Hair Regeneration Procedure Performed?
Initially, some blood will be taken from your arm and then spun in a high speed centrifuge machine to make platelet rich plasma (PRP). After that, a numbing procedure is performed which takes a few minutes. The scalp is then numb and the procedure is painless.
A combination of the PRP, stem cells and exosomes are then injected throughout the areas of the scalp where the hair follicles need to be activated. This is done in a systematic fashion to make sure all areas are covered.
At that point, the second phase of the procedure occurs, where more PRP is spread over the scalp. A microneedling procedure is performed to open up microchannels and allow the growth factors and platelets to penetrate subdermal. The entire process takes approximately one hour.
R3 is used to perform autologous therapies, where a patient’s own bone marrow or adipose stem cells were used. However, a lot of stem cells in one’s body are as old as that person is, and hence not very active. Their ability to successfully increase sufficient blood flow and allow for shair growth is inferior to umbilical cord stem cells.
Specifically, the therapeutic potential of autologous bone marrow or adipose stem cells in the treatment of older patients is impaired by a number of age-related factors such as oxidative stress, telomere length, DNA damage, disease, and long-term use of some medications.
This is in stark contrast to the youthful genotype and phenotype of neonatal tissue-derived stem cells, such as from the umbilical cord. They are better at facilitating repair and regeneration of tissue damage, creating new blood flow with superior anti-inflammatory and immunomodulatory efficacy compared to mature stem cells from one’s adipose or bone marrow.
As a result of the inferiority of autologous stem cells due to the reasons above and better results being seen with umbilical cord stem cells, R3 only uses the donor stem cells today.
Get personalized hair restoration advice—dial (844) GET-STEM.
Stem cells and exosomes act in the body through several mechanisms. They do NOT become part of a patient’s DNA, which means they do not engraft into the person’s existing cells. The predominant method of action is thought to be through paracrine mechanisms, which means “cell to cell” interaction.
They act through:
Stem Cells can also release a huge variety of molecules into the extracellular environment. These molecules, which include extracellular vesicles, lipids, free nucleic acids, and soluble proteins, exert crucial roles in repairing damaged tissue.
Along with offering MSCs for treatment of hair loss, R3 Stem Cell includes stem cell exosomes, which are a type of extracellular vesicle participating in extensive cell to cell communication for new blood flow creation.
Where do the stem cells and exosomes come from?
R3 Stem Cell’s regenerative biologics originate from umbilical cord tissue that has been donated after a scheduled c-section. No baby (or mother) is harmed during the c-section procedure. The umbilical cord tissue is normally discarded, but if the mother passes screening tests then the umbilical cord is immediately sent to the lab. The screening tests are extremely rigorous, and mandated by the USA FDA.
The lab carefully processes the umbilical cord to generate large amounts of stem cells and exosomes that are of the highest quality possible. The lab team consists of multiple PhD’s working in ISO Certified, cGMP compliant clean rooms to ensure quality assurance that exceeds USA FDA standards. The proprietary production process combines the highest potency, safety and affordability for providers to confidently offer exosome procedures.
Millions of dollars have been invested into the pharmaceutical grade production of the biologics including first rate clean rooms, bioreactors, nano-particle tracking analyzers, cytometers, PCR, tangential flow machines and real time environmental monitoring. The quality assurance testing complies with screening and testing stan¬dards consistent with the American Association of Tissue Banks, cGMP standards, FDA regulations and the highest level of any regulatory agency globally.
Connect with R3 Stem Cell now: (844) GET-STEM.
Stem Cell Derived Exosomes
R3 Stem Cell’s Centers of Excellence globally include umbilical cord stem cell derived exosomes with umbilical cord stem cells to provide enhanced results. Exosomes are lipid bound vesicles (acellular) produced by cells which contain a plethora of growth factors, cytokines, mRNA and other proteins.
They are exceptionally helpful in cell to cell communication, and very effective for reducing inflammation when they become ingested by their recipient cell. They act as shuttles to send nucleic acids and proteins to other cells, in this way, allowing cellto-cell communication and transporting molecules among both close and distant cells. In general, these released proteins are important regulators of intracellular information.
Exosomes could be the mediators of many stem cellassociated therapeutic activities. We have seen them to be “faster acting” than stem cells, so R3 frequently uses them in conjunction to provide a “1-2 punch” for patient outcomes.
Because of their regenerative potential, exosomes are now considered a powerful tool in enhancing tissue repair, reducing immune responses, and promoting healing at a cellular level. By combining exosomes with stem cell therapy, R3 Stem Cell maximizes treatment effectiveness, offering patients faster recovery times and improved overall results.
Is stem cell therapy safe?
After a decade of performing over 24,000 stem cell procedures worldwide, R3 knows that the regenerative procedures are safe. The quality control employed during the stem cell production is second to none, and the side effects R3 sees are usually mild to moderate and temporary.
They may include itching, dizziness, lightheadedness, low grade fever, chills, headache, nausea. These are typically temporary. If a patient has an allergic reaction to the multivitamin or a preservative, all of R3’s Centers have the medications to resolve it quickly.
One of the questions we get asked a lot is, “Will the stem cells get rejected?” The answer is NO.
MSCs do not express major histocompatibility complex (MHC) antigens of the class II subtype and contain low levels of MHC molecules of the class I subtype. MSCs also lack the co-stimulatory molecules essential for immune detection, including CD40, CD80, and CD86.
Therefore, MSCs generally have low immunogenicity and can avoid immune rejection by the recipient, which serves as the foundation for their successful application without needing to match the donor to the recipient. Scientists call this being “immunologically privileged”
Another question often asked is “Is there a chance of a tumor forming?” Current research has concluded that the answer is NO. The mesenchymal stem cells and exosomes used during treatment have never been shown to have tumor forming potentials. In fact, they have been shown to be anti-tumor forming.
Speak with our experts today: (844) GET-STEM.
Protocol
For the past decade, R3 has been successfully treating hair loss with stem cell and exosome injections. The scalp is numbed, so the procedure is virtually painless and tolerated well.
After numbing, R3’s providers use approximately 20 million stem cells and 50 billion exosomes for the procedure. PRP, short for platelet rich plasma therapy, is also included at no additional charge. The procedure takes less than an hour!
Outcomes
Similar to the research mentioned above, R3 Stem Cell’s outcomes for hair loss have been exceptional! The patient satisfaction rate is 85% year over year. Patients typically experience significant hair growth that is maintained for a long time. Keep in mind results cannot be guaranteed and will vary between individuals.
It may take several months to see all the improvements, as it can take that long to build up new blood flow and hair growth. It should be noted, again, that stem cell therapy is not a cure for hair loss, and will need to be repeated every 12-24 months or so for continued benefit.
Affordability
Because stem cell therapy for hair loss is not a permanent cure, it’s important to make it affordable. Repeat therapies can help maintenance and/or achieve additional improvements for hair loss. So a lot of patients seek additional treatments at R3 Stem Cell every twelve to eighteen months.
R3 Stem Cell’s fees are less than half what comparable (and reputable) regenerative clinics charge. Be wary of clinics trying to pass off PRP as a stem cell therapy. If they mention only taking your blood for the treatment, it is NOT a stem cell treatment!
R3’s Experience
For the past decade, R3 Stem Cell’s Centers globally have performed over 23,000 regenerative procedures in six countries. Several hundred have been for hair loss, along with various types of alopecia Patient satisfaction across all conditions treated is 85%!
R3 combines safety, effectiveness and affordability for the therapies. Internationally, the Intellicell is used, which is culturing the most active mesenchymal stem cells to create the “smartest” stem cell in the world!
R3 Stem Cell offers free consultations for individuals to discuss whether regenerative therapy is indicated for their hair loss. Simply call (844) GET-STEM or +1 (480) 808-7057 to schedule yours!
References
David Greene, MD, PhD, MBA, Founder/CEO
R3 Stem Cell offers treatments that bring patients hope and options. Hope that surgery can be avoided, and tissue injury can be repaired with patients being able to get back to desired activities.
Founder and CEO David Greene, MD, PhD, MBA writes extensively on regenerative medicine and gives many seminars worldwide on a regular basis. With over forty Centers of Excellence globally, R3 is at the forefront of regenerative therapies.
R3’s Centers have successfully performed over 24,000 regenerative procedures to date. Call today for your free consultation (844) GET-STEM!
No portion of this document may be reproduced without the Express Written Consent of R3 Stem Cell.
Disclaimer: This guide’s education does not constitute medical advice. The USA FDA considers stem cell therapy experimental.
Brand Ambassador Gallery
The USA stem cell leader offers procedures in
7 Countries including:
SUCCESS STORIES
R3 STEM CELL MASTER CLASS
Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!
R3 STEM CELL INTERNATIONAL
R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.
FREE STEM CELL CONSULTATION
R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.
PROVIDER PARTNERSHIP
The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!
The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only your medical professional can explain all the risks and potential benefits of any therapy based on your circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.
CALIFORNIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEBRASKA
NEW JERSEY
NEW YORK
NEW MEXICO
NEVADA
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
Disclaimer: The city links above provide general information on stem cell treatment. To find an R3 Stem Cell clinic near you click here
The USA stem cell leader offers procedures in
7 Countries including:
Copyright © 2017-2025 R3 Stem Cell. All Rights Reserved.
